-
Clin Cancer Res: PARP inhibitor Veliparib combined with optimized FOLFIRI as a second-line treatment for metastatic pancreatic cancer
Time of Update: 2021-12-24
The study is a randomized phase II trial designed to evaluate the efficacy and safety of mFOLFIRI combined with Veliparib vs FOLFIRI (control: irinotecan, fluorouracil, leucovorin) as a second-line treatment for metastatic pancreatic cancer .
-
Front Oncol: Stereotactic radiotherapy (SBRT) combined with immunotherapy (SBRT-IO) compared with TACE in the treatment of patients with locally advanced hepatocellular carcinoma
Time of Update: 2021-12-24
Propensity score matching (PSM) analysis was used to compare the effectiveness and safety of SBRT-IO and TACE in the treatment of locally advanced HCC patients .
The median PFS of the SBRT-IO group and TACE group were unreached (range: 1.
-
Clin Cancer Res: The effect of fulvestrant + everolimus + anastrozole in the first-line treatment of HR-positive advanced breast cancer
Time of Update: 2021-12-24
A randomized trial of fulvestrant, everolimus and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222 .
-
What does the increased proportion of split red blood cells indicate after transplantation?
Time of Update: 2021-12-24
The former includes hemolysis caused by donor and recipient ABO blood group incompatibility, graft versus host disease (GVHD), and transplantation-related thrombotic microangiopathic anemia ( TA-TMA) .
-
White ivory sign is very different for children and adults
Time of Update: 2021-12-24
Ivory vertebra sign refers to the diffuse and uniform density of the vertebral body, without changes in the size and shape of the vertebral body, and the density and size of the adjacent discs .
-
BMC Cancer: Efficacy and safety of cisplatin plus etoposide (EP) vs carboplatin plus etoposide (EC) in the treatment of extensive-stage SCLC
Time of Update: 2021-12-24
In summary, studies have shown that there is no significant difference between EC and EP regimens in the first-line treatment of patients with extensive-stage SCLC .
There is no significant difference between EC and EP regimens in the first-line treatment of patients with extensive-stage SCLC .
-
19 new Class 1 drugs were added this week, and 6 clinical trials in the field of domestic oncology drugs were approved
Time of Update: 2021-12-24
(People's Daily Health Client Li Xuanzhang) As of December 11, 2021, data from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration shows that a total of 5,980 clinical trial applications have passed "implicit permission .
-
CSCO NSCLC Guide 2021: Changes in immunotherapy medication are summarized!
Time of Update: 2021-12-24
Secretary of the Youth Expert Committee of Lung Cancer of Beijing Medical Awards Foundation, member of the Professional Committee of Geriatric Oncology of the Chinese Society of Gerontology, member of the Professional Committee of Lung Cancer of Beijing Anti-Cancer Association
-
Nat Med: The safety and efficacy of Avapritinib in the treatment of advanced systemic mastocytosis
Time of Update: 2021-12-24
This phase 1 study (NCT02561988) in patients with advanced systemic mastocytosis was to evaluate Avapritinib (BLU-285), a selective KITD816V The efficacy of inhibitors .
Researchers evaluated 86 patients with a therapeutic dose of 30-400mg Avapritinib once a day, 69 of which were diagnosed with advanced systemic mastocytosis .
-
Neurology: Attention people with family history!
Time of Update: 2021-12-24
Recent neurology scholars from Utrecht University Medical Center combined individual patient data (IPD) from a prospective cohort of patients with unruptured intracranial aneurysms to assess the degree of rupture risk in patients with familial aneurysms compared to sporadic aneurysms The results were published in the journal Neurology .
-
Clin Cancer Res: The new BTK inhibitor Zanubrutinib is used to treat relapsed/refractory marginal zone lymphoma
Time of Update: 2021-12-24
Zanubrutinib has shown a high objective remission rate and complete remission rate in patients with relapsed/refractory marginal zone lymphoma, and has a long-lasting disease control effect and good safety .
-
NEJM: Menopausal status will affect the benefit of chemotherapy-endocrine combination therapy for patients with axillary lymph node-positive breast cancer
Time of Update: 2021-12-24
Recently, researchers investigated the role of recurrence risk score in predicting the benefit of adjuvant chemotherapy in patients with axillary lymph node-positive breast cancer .
Recently, researchers investigated the role of recurrence risk score in predicting the benefit of adjuvant chemotherapy in patients with axillary lymph node-positive breast cancer .
-
Disappointed!
Time of Update: 2021-12-24
In 2013, tumor biologist Elizabeth Iorns initiated an ambitious project-Reproducibility Project (Cancer Biology) in the field of cancer biology, which aims to verify 53 high-impact cancer biology articles from 2010 to 2012 The reproducibility of related research papers, and the repeated results will be published in the eLife journal .
-
Eur Urol: Differential Response Analysis of Different Molecular Subtypes of Urothelial Carcinoma to Neoadjuvant Chemotherapy
Time of Update: 2021-12-24
Recently, researchers from Sweden published an article on the "Eur Urol" magazine, investigated how different molecular subtypes influence pathological response and students before preoperative chemotherapy of cisplatin deposit rate .
Among the predetermined molecular subtypes, the researchers compared the complete pathological response (ypT0N0) and survival rates of cystectomy samples .
-
Cancer Cell: All cancers can be simply divided into two categories, according to whether they express YAP protein
Time of Update: 2021-12-24
Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activityThe study shows that all cancers can be divided into two categories based on whether they express YAP protein.
-
J Clin Oncol: The effect of adding Pabocicide to the endocrine therapy of early breast cancer
Time of Update: 2021-12-24
Adding Pabocinil to standard endocrine therapy does not further improve the prognosis of early hormone receptor positive breast cancer.
Adding Pabocinil to standard endocrine therapy does not further improve the prognosis of early hormone receptor positive breast cancer.
-
I don't want you to think, I want me to think!
Time of Update: 2021-12-24
Women with breast cancer who self-rated psychological distress increased the risk of death by 46% (adjusted HR: 1.
Women with breast cancer who self-rated psychological distress increased the risk of death by 46% (adjusted HR: 1.
-
Front Oncol: Efficacy and safety of Lenvatinib as a single agent or combined with PD-1 inhibitors in the treatment of Chinese patients with advanced liver cancer
Time of Update: 2021-12-24
HCC monotherapy for OS and PFSThe mOS and mPFS of the lenvatinib combined with PD-1 inhibitor treatment group of HCC patients were 21.
HCC combined treatment of OS and PFSHowever, the mOS of the lenvatinib combined with PD-1 inhibitor treatment group of ICC patients has not yet reached; and the mPFS is 8.
-
Nat Med: Safety and efficacy of Avapritinib in patients with advanced systemic mastocytosis
Time of Update: 2021-12-24
The primary endpoint of the study is the overall response rate (ORR), and the secondary endpoints include patients with chronic systemic mastocytosis-symptom assessment table total symptom score and average baseline change in quality of life, response time, response duration, and progression-free survival Changes in life, overall survival, disease burden, and safety indicators .
-
Roche's PD-L1+TIGIT dual target is used in the first-line NSCLC treatment, the effect is amazing, and the risk of OS death is reduced by 71%
Time of Update: 2021-12-24
On December 10, Roche announced the latest data on the PD-L1 antibody + TIGIT antibody combined with the first-line treatment of NSCLC Phase II clinical CITYSCAPE .
